Medicines Co. (MDCO)


The Medicines Company is committed to delivering innovative, cost-effective acute care products in the worldwide hospital marketplace. The Company markets Angiomax® (bivalirudin) in the U.S. and other countries for use in patients undergoing coronary angioplasty, a procedure to clear restricted blood flow in arteries around the heart. The Company also has two products in late-stage development, Cleviprex(TM) (clevidipine) and cangrelor. The Company's website is

Contact Information

8 Campus Drive
Parsippany, NJ 07054

tel: 973-656-1616
fax: 973-656-9898


Investor Relations



Exchange: NASDAQ
Industry: Drug Manufacturers - Other
Market Cap: $1B

The information provided here has been obtained from publicly available sources as well as directly from issuers in some cases. Please see our Disclaimer and Terms of Service for more information.